Press Release: Mavupharma : Mavupharma Selects First Immuno-Oncology Clinical Candidate MAVU-104, an Oral STING Pathway Enhancer

KIRKLAND, Wash., Jan. 3, 2019 /PRNewswire/ -- Mavupharma (Mavu) announced today that it has selected its first immuno-oncology clinical development candidate, MAVU-104, a novel innate immune modulator.